000			02768na a2200289 4500
999			_c551 _d551
003			PC551
005			20181122133650.0
008			130622s2013 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_aSánchez Torres, José Miguel _91179 _eOncología Médica
245	0	0	_aPrevalence and management of anaemia in patients with non-myeloid cancer undergoing systemic therapy: a Spanish survey. _h[artículo]
260			_c2013 _bClinical & Translational Oncology.
300			_a15(6):477-83.
500			_aFormato Vancouver: Steegmann JL, Sánchez Torres JM, Colomer R, Vaz Á, López J, Jalón I et al. Prevalence and management of anaemia in patients with non-myeloid cancer undergoing systemic therapy: a Spanish survey. Clin Transl Oncol. 2013 Jun;15(6):477-83.
501			_aPMID: 23263906
504			_aContiene 28 referencias
520			_aThe present study aimed to provide updated data on anaemia prevalence and management in cancer patients undergoing systemic therapy in Spain. This was a multicenter, observational, cross-sectional study performed in 2008. Eligible patients were a parts per thousand yen18 years, with non-myeloid malignancies treated with systemic therapy [chemotherapy (CT), hormonal therapy or immunotherapy]. Anaemia was defined according to WHO as haemoglobin (Hb) < 12 g/dL. The study included 214 patients with a median age of 63 years (range 20-91), 58 % women, 73 % with solid tumours, and 79 % with advanced disease. CT was used in 91 % of patients (26 % with platinum compounds), hormonal therapy in 8.5 %, and immunotherapy in 8.5 %. In our study, 48.1 % of patients [95 % confidence interval (CI) 45.2-58.6] showed anaemia (31 % symptomatic): 42.0 % mild (10 a parts per thousand currency sign Hb a parts per thousand currency sign 11.9 g/dL), 5.6 % moderate (8 a parts per thousand currency sign Hb a parts per thousand currency sign 9.9 g/dL), and 0.5 % severe (Hb < 8 g/dL). A higher prevalence was observed in patients treated with CT (51 vs. 20 %, p = 0.01), platinum-based CT (70 vs. 47 %, p = 0.01) or palliative CT (61 vs. 39 %, p = 0.003). Anaemia was also more frequent in patients with more than three lines of CT (83 %) and in the fourth or subsequent CT cycle (58 %). Management in the previous 4 weeks in patients with anaemia was: 62 % did not receive treatment (92 % mild), 24 % received erythropoiesis-stimulating agents (ESAs), 14 % received iron and 8.7 % received transfusion. In Spanish hospitals, about half of patients with non-myeloid malignancies undergoing systemic therapy fulfilled anaemia criteria (87 % mild). Approximately two-third of patients with anaemia do not receive specific treatment and ESA use is below current guidelines.
710			_9303 _aServicio de Oncología Médica
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/5/pc551.pdf _ySolicitar documento
942			_n0 _2ddc _cART